Notice of Allowability	Application No.	Applicant(s)
	10/657,932	ROGERS ET AL.
	Examiner	Art Unit
	Sudhaker B. Patel, D.Sc.Tech.	1624
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject t	oplication. If not included n will be mailed in due course. THIS
1. This communication is responsive to <u>9/9/03</u> .		
2. The allowed claim(s) is/are <u>53-68</u> .		
3. The drawings filed on are accepted by the Examiner	r.	
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents nave International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" on the below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> <li>5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date  (b) ☐ including changes required by the attached Examiner's Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the composition of the deposit attached Examiner's comment regarding REQUIREMENT is attached Examiner's comment regarding REQUI</li></ul>	been received.  been received in Application No cuments have been received in this  of this communication to file a reply ENT of this application.  itted. Note the attached EXAMINER es reason(s) why the oath or declara to be submitted. on's Patent Drawing Review ( PTO- a Amendment / Comment or in the Comment or in the Comment of BIOLOGICAL MATERIAL I	national stage application from the complying with the requirements at a C'S AMENDMENT or NOTICE OF ation is deficient.  -948) attached  Office action of the back) of (d).  must be submitted. Note the
Attachment(s)  1. ☑ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Summary Paper No./Mail Da 7. Examiner's Amendr 8. Examiner's Stateme 9. Other RICHARD PRIMARY	te

Art Unit: 1624

## **REASONS FOR ALLOWANCE**

Page 2

1. The following is an examiner's statement of reasons for allowance:

- 2. Applicants' preliminary amendment dated 9/9/03 is acknowledged. Applicants have cancelled claims 1-52 and presented new claims 53-68. Therefore, the claims under consideration are the claims 53-68 which are renumbered as claims 1-16 respectively.
- 3. The closest prior art of record reference Chandrakumar et al (WO 9952896) teaches making of heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists. See Example 2 on page 95 which has a core:
  - "Substituted pyridine-CO-NH-CH2-CO-NH-CH (CH2-COOH)-substituted phenyl".

The reference differs from the instant compounds by not having hydrogenated stilbene core.

- 4. The other prior art reference Duggan et al (U.S.P. 5919792 dated 7/1999) teaches compounds with heterocycle-NH-CH2-aryl-CO-NH-CH2-HC (COOH)-NHSO2Ph (See columns 29-30, compound 2-5) andPyridine-CH2-CH2-Phenyl-CO-NH-CH2-CH (COOH)-NH-SO2-Phenyl (See compound 5-10 in columns 41-42) and their utility as claimed herein. The ref. differs from the instant compounds by not having dihydrostibene core as claimed herein.
- 5. The references either alone or in combination do not teach or indicate to arriving at the instant compounds having a core:
  - "Substituted heterocycle-NH- (CH2) 3-O-Phenyl-SO2-NH-CH (-CH2-Phenyl)/-CH20pyridine)-CH2-COOH". See instant Example 13 on page 78 and Example 14 on page 81. i.e. dihydrostilbene derivatives
- 6. Therefore, the instant invention is deemed to be novel and patentably distinct.
- 7. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671. The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James O. Wilson at (571) 272-0661.
- 9. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.
- 10. Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703 308

1235.Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sudhaker B. Patel, D.Sc. Tech.

June 21, 2004

MUKERWARS EXAMINER

SUPERVISOR PAPATENT

**EXAMINER** 

ART UNIT 1624/1623

## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C07D 401/12, A61K 31/44, C07K 5/023, C07D 213/82, 495/10, 409/12, 333/38, 403/12, 417/12

(11) International Publication Number:

WO 99/52896

(43) International Publication Date:

21 October 1999 (21.10.99)

(21) International Application Number:

(22) International Filing Date:

PCT/US99/04297

A1

9 April 1999 (09.04.99)

(30) Priority Data:

60/081,394

10 April 1998 (10.04.98)

US

(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(72) Inventors; and

(75) Inventors, and
(75) Inventors/Applicants (for US only): CHANDRAKUMAR,
Nizal, Samuel [IN/US]; 15 Montgomery Lane, Vernon
Hills, IL 60061 (US). DESAI, Bipinchandra, Nanubhai
[US/US]; 200 Annapolis Drive, Vernon Hills, IL 60061
(US). DEVADAS, Balekudru [US/US]; 2175 Parasol Drive,
Chesterfield, MO 63017 (US). HUFF, Renee [US/US];
837 N. Lincoln Avenue, Park Ridge, IL 60068 (US).
KHANNA, Ish, K. [US/US]; 149 Brandywine Court, Vernon
Hills, IL 60061 (US). RAO, Shashidhar, N. [IN/US]; 43
Windsor Place, Mundelein, IL 60060 (US). RICO, Joseph,
G. [US/US]; 524 Weatherby Terrace Drive, Ballwin, MO
63021 (US). ROGERS, Thomas, E. [US/US]; 755 Trago
Creek Drive, Ballwin, MO 63021 (US). RUMINSKI, Peter,

G. [US/US]; 7687 Pierside Drive, Dardenne Prairie, MO 63366 (US). RUSSELL, Mark, Andrew [US/US]; 475 Cross Road, Gurnee, IL 60031 (US). YU, Yi [CN/US]; Apartment #GR, 9065 Gross Point Road, Skokie, IL 60077 (US). GASIECKI, Alan, Frank [US/US]; 105 Alexandria Drive, Vernon Hills, IL 60061 (US). MALECHA, James, W. [US/US]; 1121 Tracy Lane, Libertyville, IL 60048 (US). MIYASHIRO, Julie, M. [US/US]; 4654 W. Keeney #3W, Skokie, IL 60076 (US).

- (74) Agents: KOVACEVIC, Cynthia, S. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).
- (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS

$$A = \begin{pmatrix} Y^3 \\ C \\ Z^3 \end{pmatrix}_L \begin{pmatrix} X^1 \\ HET \\ Z \end{pmatrix}_{n} \begin{pmatrix} Y \\ C \\ Z \end{pmatrix}_{n} \begin{pmatrix} CH_2 \\ N-CH \\ R^{11} \\ R^{1} \end{pmatrix} \begin{pmatrix} CH_2 \\ N-CH \\ R^{11} \\ R^{1} \end{pmatrix}$$

(57) Abstract

The present invention relates to a class of compounds represented by formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and methods of treating conditions mediated by the  $\alpha_v \beta_3$  integrin.